Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective raised by stock analysts at Royal Bank Of Canada from $151.00 to $155.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 18.18% from the stock’s previous close.

JAZZ has been the subject of a number of other research reports. JPMorgan Chase & Co. cut their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a report on Monday, October 27th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective for the company. Morgan Stanley set a $183.00 price target on Jazz Pharmaceuticals in a research report on Friday, October 24th. Wells Fargo & Company set a $170.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 22nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $178.50.

Jazz Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ JAZZ opened at $131.16 on Thursday. The company has a market capitalization of $7.97 billion, a P/E ratio of -19.49, a P/E/G ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The company has a 50 day simple moving average of $133.21 and a 200-day simple moving average of $119.30.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, beating analysts’ consensus estimates of $5.87 by $2.26. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same quarter in the prior year, the company posted $6.54 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was up 6.7% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, equities research analysts predict that Jazz Pharmaceuticals will post 16.96 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the sale, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 11,500 shares of company stock worth $1,525,280 in the last three months. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Hurley Capital LLC acquired a new position in Jazz Pharmaceuticals during the first quarter worth $25,000. Picton Mahoney Asset Management increased its position in shares of Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after acquiring an additional 269 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 234 shares during the last quarter. SVB Wealth LLC bought a new position in Jazz Pharmaceuticals in the 1st quarter valued at about $36,000. Finally, Hantz Financial Services Inc. lifted its position in Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 297 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.